View in EDS

Hallmarks of Resistance to Immune-Checkpoint Inhibitors.

Saved in:
Bibliographic Details
Title: Hallmarks of Resistance to Immune-Checkpoint Inhibitors.
Authors: Karasarides M; Worldwide Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey., Cogdill AP; Immunai, New York, New York.; Department of Immunology, The University of Texas MD Anderson, Houston, Texas., Robbins PB; Instil Bio, Dallas, Texas., Bowden M; Translational Medicine, Bristol Myers Squibb, Cambridge, Massachusetts., Burton EM; Department of Surgical Oncology, The University of Texas MD Anderson, Houston, Texas., Butterfield LH; Parker Institute for Cancer Immunotherapy, San Francisco, California.; Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California., Cesano A; ESSA Pharma Inc., South San Francisco, California., Hammer C; Department of Cancer Immunology, Genentech, South San Francisco, California.; Department of Human Genetics, Genentech, South San Francisco, California., Haymaker CL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Horak CE; Global Drug Development, Bristol Myers Squibb, Lawrenceville, New Jersey., McGee HM; Department of Radiation Oncology, City of Hope National Medical Center and Department of Immuno-Oncology, Beckmann Research Institute, City of Hope, Duarte, California., Monette A; Lady Davis Institute for Medical Research, Montréal, Québec, Canada., Rudqvist NP; University of Texas MD Anderson Cancer Center, Houston, Texas., Spencer CN; Department of Informatics, Parker Institute for Cancer Immunotherapy, San Francisco, California.; University of California San Francisco, San Francisco, California., Sweis RF; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.; Committee on Immunology, University of Chicago, Chicago, Illinois.; Comprehensive Cancer Center, University of Chicago, Chicago, Illinois., Vincent BG; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina., Wennerberg E; The Institute of Cancer Research, London, UK., Yuan J; Translational Oncology, Early Oncology Development Department, Merck Research Laboratories, Rahway, New Jersey., Zappasodi R; Weill Cornell Medicine, New York, New York.; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York.; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York., Lucey VMH; Worldwide Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey., Wells DK; Immunai, New York, New York.; Parker Institute for Cancer Immunotherapy, San Francisco, California., LaVallee T; Parker Institute for Cancer Immunotherapy, San Francisco, California.
Source: Cancer immunology research [Cancer Immunol Res] 2022 Apr 01; Vol. 10 (4), pp. 372-383.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35362046
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Hallmarks of Resistance to Immune-Checkpoint Inhibitors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Karasarides+M%22">Karasarides M</searchLink>; Worldwide Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey.<br /><searchLink fieldCode="AU" term="%22Cogdill+AP%22">Cogdill AP</searchLink>; Immunai, New York, New York.; Department of Immunology, The University of Texas MD Anderson, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Robbins+PB%22">Robbins PB</searchLink>; Instil Bio, Dallas, Texas.<br /><searchLink fieldCode="AU" term="%22Bowden+M%22">Bowden M</searchLink>; Translational Medicine, Bristol Myers Squibb, Cambridge, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Burton+EM%22">Burton EM</searchLink>; Department of Surgical Oncology, The University of Texas MD Anderson, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Butterfield+LH%22">Butterfield LH</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California.; Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Cesano+A%22">Cesano A</searchLink>; ESSA Pharma Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Hammer+C%22">Hammer C</searchLink>; Department of Cancer Immunology, Genentech, South San Francisco, California.; Department of Human Genetics, Genentech, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Haymaker+CL%22">Haymaker CL</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Horak+CE%22">Horak CE</searchLink>; Global Drug Development, Bristol Myers Squibb, Lawrenceville, New Jersey.<br /><searchLink fieldCode="AU" term="%22McGee+HM%22">McGee HM</searchLink>; Department of Radiation Oncology, City of Hope National Medical Center and Department of Immuno-Oncology, Beckmann Research Institute, City of Hope, Duarte, California.<br /><searchLink fieldCode="AU" term="%22Monette+A%22">Monette A</searchLink>; Lady Davis Institute for Medical Research, Montréal, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Rudqvist+NP%22">Rudqvist NP</searchLink>; University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Spencer+CN%22">Spencer CN</searchLink>; Department of Informatics, Parker Institute for Cancer Immunotherapy, San Francisco, California.; University of California San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Sweis+RF%22">Sweis RF</searchLink>; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.; Committee on Immunology, University of Chicago, Chicago, Illinois.; Comprehensive Cancer Center, University of Chicago, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Vincent+BG%22">Vincent BG</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.<br /><searchLink fieldCode="AU" term="%22Wennerberg+E%22">Wennerberg E</searchLink>; The Institute of Cancer Research, London, UK.<br /><searchLink fieldCode="AU" term="%22Yuan+J%22">Yuan J</searchLink>; Translational Oncology, Early Oncology Development Department, Merck Research Laboratories, Rahway, New Jersey.<br /><searchLink fieldCode="AU" term="%22Zappasodi+R%22">Zappasodi R</searchLink>; Weill Cornell Medicine, New York, New York.; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York.; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York.<br /><searchLink fieldCode="AU" term="%22Lucey+VMH%22">Lucey VMH</searchLink>; Worldwide Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey.<br /><searchLink fieldCode="AU" term="%22Wells+DK%22">Wells DK</searchLink>; Immunai, New York, New York.; Parker Institute for Cancer Immunotherapy, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22LaVallee+T%22">LaVallee T</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101614637%22">Cancer immunology research</searchLink> [Cancer Immunol Res] 2022 Apr 01; Vol. 10 (4), pp. 372-383.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101614637 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2326-6074 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223266066%22">23266066 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Immunol Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35362046
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/2326-6066.CIR-20-0586
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 372
    Titles:
      – TitleFull: Hallmarks of Resistance to Immune-Checkpoint Inhibitors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Karasarides M
      – PersonEntity:
          Name:
            NameFull: Cogdill AP
      – PersonEntity:
          Name:
            NameFull: Robbins PB
      – PersonEntity:
          Name:
            NameFull: Bowden M
      – PersonEntity:
          Name:
            NameFull: Burton EM
      – PersonEntity:
          Name:
            NameFull: Butterfield LH
      – PersonEntity:
          Name:
            NameFull: Cesano A
      – PersonEntity:
          Name:
            NameFull: Hammer C
      – PersonEntity:
          Name:
            NameFull: Haymaker CL
      – PersonEntity:
          Name:
            NameFull: Horak CE
      – PersonEntity:
          Name:
            NameFull: McGee HM
      – PersonEntity:
          Name:
            NameFull: Monette A
      – PersonEntity:
          Name:
            NameFull: Rudqvist NP
      – PersonEntity:
          Name:
            NameFull: Spencer CN
      – PersonEntity:
          Name:
            NameFull: Sweis RF
      – PersonEntity:
          Name:
            NameFull: Vincent BG
      – PersonEntity:
          Name:
            NameFull: Wennerberg E
      – PersonEntity:
          Name:
            NameFull: Yuan J
      – PersonEntity:
          Name:
            NameFull: Zappasodi R
      – PersonEntity:
          Name:
            NameFull: Lucey VMH
      – PersonEntity:
          Name:
            NameFull: Wells DK
      – PersonEntity:
          Name:
            NameFull: LaVallee T
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2022 Apr 01
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2326-6074
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Cancer immunology research
              Type: main
ResultId 1